Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22

TCR directed to a novel C*07:02-restricted epitope of MAGEA1, TSC-204-C07, on track for IND submission in 2H22

Multiplexing TCRs in vitro leads to cytotoxicity of target cell lines and cytokine-mediated enhancement of anti-tumor activity of specific TCR cells

ImmunoBank enables customized multiplexing of TCRs across both targets and HLA restrictions

Hosting virtual KOL event May 19, 2022 at 4:30 p.m. ET to share preclinical data highlights

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ( TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, presented two posters and an oral presentation around TScans proprietary platform technologies for its solid tumor program at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

The initial preclinical data on our solid tumor program presented at ASGCT demonstrate the capability of TScans proprietary platforms to identify novel TCRs. Through ReceptorScan, we identified TSC-200-A02 that targets an HLA-A*02:01 restricted epitope of HPV16-E7 and with TargetScan we identified TSC-204-C07 targeting a novel HLA-C*07:02 restricted epitope of MAGE-A1. We are excited to report initial preclinical results, which showed strong cytoxicity of TSC-200-A02 in HPV+ target cell lines and no off-target activity. When we multiplexed the two TCRs in vitro, we were excited to see synergistic cytotoxic activity. said Gavin MacBeath, Ph.D., Chief Scientific Officer.

Dr. MacBeath continued, We are on track to continue progressing IND-enabling studies for the TSC-200 series and submitting IND applications for TSC-200-A02 and TSC-204-C7 during the second half of this year. These initial preclinical results suggest that multiplexing TCRs has the potential to overcome both tumor antigen heterogeneity and HLA loss-of-heterozygosity (LOH).

Presentation Highlights:

Poster presentation titled Discovery of TSC-200-A02: A natural HPV16 E7-specific TCR-T cell therapy candidate for the treatment of HPV-positive solid tumors, presented by Gavin MacBeath, Ph.D.

Poster presentation titled Multiplexed TCR-T cell therapy: A strategy to enhance the efficacy of engineered T cell therapy, presented by Gavin MacBeath, Ph.D.

Oral presentation titled Discovery of a novel C*07:02-restriced epitope on MAGE-A1 and pre-clinical development of an enhanced TCR-T cell therapy candidate for the treatment of solid tumors, presented by Gavin MacBeath, Ph.D.

A copy of the presentation materials can be accessed on the Events and Presentations section of the Companys Investor Relations website at http://www.ir.tscan.com.

Virtual KOL Event

The Company is hosting a virtual KOL event today, Thursday, May 19, 2022, at 4:30 p.m. ET, featuring Kai Wucherpfennig, M.D., Ph.D. Chair, Cancer Immunology and Virology and Director, Center for Cancer Immunology Research at the Dana-Farber Cancer Institute, Professor of Neurology, Brigham and Womens Hospital and Harvard Medical School, and Associate Member, Broad Institute of MIT and Harvard. The event will provide an in-depth review of the oral and poster presentations related to solid tumor TCR-T therapy candidates, TSC-200-A02 for HPV16, and TSC-204-C07 for MAGE-A1, as well as TScans approach to potentially overcome antigen heterogeneity and HLA loss with multiplexed TCR-T. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to [emailprotected]. Registration for the live event can be found here. A replay will be available on the Events and Presentations section of the Companys website at ir.tscan.com.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Companys lead leukemia TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Companys bank of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with various types of solid tumors.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding current and future research and development plans or expectations, the structure, timing and success of the Companys planned preclinical development, submission of INDs, and clinical trials, the potential benefits of any of the Companys proprietary platforms or current or future product candidates in treating patients, and the Companys goals, strategy, business plans and focus, among other things. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, may, might, will, objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design, estimate, predict, potential, plan, on track, or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScans TCR-T therapy candidates; TScans expectations regarding its preclinical studies being predictive of clinical trial results; the timing of the initiation, progress and expected results of TScans preclinical studies, clinical trials and its research and development programs; TScans plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScans TCR-T therapy candidates; TScans manufacturing capabilities and the scalable nature of its manufacturing process; TScans estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScans expectations regarding competition; TScans anticipated growth strategies; TScans ability to attract or retain key personnel; TScans ability to establish and maintain development partnerships and collaborations; TScans expectations regarding federal, state and foreign regulatory requirements; TScans ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScans existing capital resources to fund its future operating expenses and capital expenditure requirements; and the effect of the COVID-19 pandemic, including mitigation efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of TScans business or operations; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of TScans Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 9, 2022 and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScans views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Contacts

Heather Savelle TScan Therapeutics, Inc. VP, Investor Relations 857-399-9840 [emailprotected]

Joyce Allaire LifeSci Advisors, LLC Managing Director 617-435-6602 [emailprotected]

More:
TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting - GuruFocus.com